Assaad Mahmoud, Singh Robby, Sarsam Sinan, Bowen Abbie, Zughaib Marcel
1 Providence Hospital/Michigan State University, Southfield, MI, USA.
2 Department of Cardiology, Providence-Providence Park Hospital, Southfield, MI, USA.
J Int Med Res. 2018 Aug;46(8):3195-3199. doi: 10.1177/0300060518774123. Epub 2018 May 28.
Introduction Congestive heart failure is a leading cause of cardiovascular mortality and morbidity in the United States and places a significant economic burden on the health care system. The CHAMPION trial showed significant reductions in heart failure hospitalizations and length of stay as well as improvements in quality of life among patients who underwent implantation of the CardioMEMS device (CardioMEMS Inc., Atlanta, GA, USA). While the benefits of the device have been well demonstrated, we explored the "pseudo-placebo" effect of device placement on patients' lifestyle modifications. Methods Thirty patients with the CardioMEMS device were contacted for a follow-up survey that included questions about lifestyle modifications, symptomatic and dietary improvement, increased physical activity, and changes in their cardiac medication regimen. Results Dyspnea improved in 57% of patients, 70% of patients improved their diet, and 43% increased their physical activity. Only 7% of patients found it difficult to transmit the data. Discussion The CHAMPION trial showed numerous benefits for patients who underwent CardioMEMS device placement. In our study, we found that device placement also resulted in a "pseudo-placebo" effect with most patients making positive lifestyle modifications.
引言
在美国，充血性心力衰竭是心血管疾病死亡率和发病率的主要原因，给医疗保健系统带来了巨大的经济负担。CHAMPION试验表明，接受CardioMEMS装置（美国佐治亚州亚特兰大市CardioMEMS公司）植入的患者，心力衰竭住院率和住院时间显著降低，生活质量也有所改善。虽然该装置的益处已得到充分证明，但我们探讨了装置植入对患者生活方式改变的“假安慰剂”效应。
方法
我们联系了30名植入CardioMEMS装置的患者进行随访调查，调查内容包括生活方式改变、症状和饮食改善、身体活动增加以及心脏用药方案的变化等问题。
结果
57%的患者呼吸困难有所改善；70%的患者饮食得到改善；43%的患者身体活动增加。只有7%的患者发现数据传输困难。
讨论
CHAMPION试验表明，接受CardioMEMS装置植入的患者有诸多益处。在我们的研究中，我们发现装置植入还产生了“假安慰剂”效应，大多数患者的生活方式得到了积极改善。
